Abstract
The present study evaluated99mTc(V) DMSA as an agent for the visualization of inflammatory lesions in comparison to99mTc(HI) DMSA and99mTc-HIG. All three radiopharmaceuticals were prepared with commercial kits.99mTc(V) DMSA was prepared at neutral pH by the addition of first bicarbonate and then pertechnetate to the kit contents. The labeling efficiency was 99% as determined by ITLC. Abscesses were induced by i.m. injection of 50 μl turpentine into the right thighs of 36 Swiss albino mice. Six days later 3.7 MBq of each radiopharmaceutical was i.v. administered to 12 mice. The mice were sacrificed at 1,3,6 and 24 h later. Scintigrams were obtained with a gamma camera. The abscesses were better visualized on scintigrams with99mTc(V) DMSA compared to99mTc(III) DMSA, starting at 1 h. The animals were dissected and the organs were removed, weighed and the radioactivity determined with a gamma counter. The abscess to other tissue ratios were higher with99mTc(V) DMSA than the other radiopharmaceuticals. The max. abscess/muscle ratios were 9.46 ± 3.20 (24 h), 4.19 ± 1.39 (6 h) and 5.98 ± 1.17 (24 h) and max. abscess/blood ratios were 6.22 ± 1.41, 4.09 ± 0.84 and 0.914 ± 0.351 all at 24 h for99mTc(V) DMSA,99mTc(III) DMSA and99mTc-HIG, respectively.
Experimental arthritis was produced in 6 New Zealand white rabbits by intra-articular injection of ovalbumin. Four days later 37 MBq of99mTc(V) DMSA and99mTc-HIG were each i.v. administered to 3 rabbits. Scintigrams obtained at 1, 3, 6, and 24 h clearly demonstrated arthritic joints. ROFs over arthritic joints were compared to contralateral normal joints (A/C). The max. A/C ratios were 2.10 ± 0.31 (3 h) and 2.92 ± 0.99 (24 h) for99mTc(V) DMSA and99mTc-HIG, respectively.
Our results indicated the feasibility of imaging inflammatory lesions with99mTc(V) DMSA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yokoyama A, Hata N, Horiuchi K, et al. The design of a pentavalent99mTc-dimercaptosuccinate complex as a tumor imaging agent.Int J Nucl Med Biol 12: 273–279, 1985.
Chauhan UPS, Babbar A, Kashyap R, et al. Evaluation of a DMSA kit for instant preparation of99mTc(V)-DMS A for tumour and metastasis scintigraphy.Nucl Med Biol 19: 825–830, 1992.
Watkinson JC, Allen SJ, Laws DE, et al. The pharmacokinetics and biodistribution of technetium-99m(V) dimercaptosuccinic acid in an animal model.J Nucl Med 32: 1235–1238, 1991.
Ohta H, Endo K, Fujita T, et al. Imaging of soft tissue tumors with Tc(V)-99m dimercaptosuccinic acid. A new tumorseeking agent.Clin Nucl Med 9: 568–573, 1984.
Watkinson JC, Larazus CR, Mistry R, et al. Technetium-99m(V) dimercaptosuccinic acid uptake in patients with squamous carcinoma of the head and neck—Experience in imaging.J Nucl Med 30: 174–180, 1989.
Kashyap R, Babber A, Sahai I, et al. Tc-99m(V) DMSA imaging. A new approach to studying metastases from breast carcinoma.Clin Nucl Med 17: 119–122, 1992.
Kobayashi H, Sakahara H, Hosono M, et al. Soft tissue tumors: Diagnosis with Tc-99m(V) dimercaptosuccinic acid scintigraphy.Radiology 190: 277–280, 1994.
Blower PJ, Sing J, Clarke SEM. The chemical identity of pentavalent technetium-99m-dimercaptosuccinic acid.J Nucl Med 32: 845–849, 1991.
Ohta H, Ishii M, Yoshizumi M, et al. A comparison of the tumor-seeking agent Tc-99m(V) dimercaptosuccinic acid and the renal imaging agent Tc-99m dimercaptosuccinic acid in humans.Clin Nucl Med 10: 167–170, 1985.
Ercan MT, Ünlenen E. Accumulation of some small molecular weight complexes of99mTc in experimental abscesses.Nucl Med Biol 21: 143–149, 1994.
Gülaldi NCM, Bayhan H, Ercan MT, et al. The visualization of pulmonary tuberculosis with Tc-99m(V) DMSA and Tc-99m citrate in comparison to Ga-67 citrate.Clin Nucl Med 20: 1012–1014, 1995.
Sampson C. Preparation of Tc-99m(V) DMSA.Nucl Med Commun 8: 184–185, 1987.
Babber A, Kashyap R, Chauhan UPS. A convenient method for the preparation of99mTc-labelled pentavalent DMSA and its evaluation as a tumor imaging agent.J Nucl Biol Med 35: 100–104, 1991.
Consden R, Doble A, Glynn LE, et al. Production of a chronic arthritis with ovalbumin. Its retention in the rabbit knee joint.Ann Rheum Dis 30: 307–315, 1971.
Ercan MT, Aras T, Ünlenen Es et al.99mTc-Citrate versus67Ga-citrate for the scintigraphic visualization of inflammatory lesions.Nucl Med Biol 20: 881–887, 1993.
Ercan MT, Ünlenen E, Aktaç A. “Tcm-glutathione for imaging inflammatory lesions.Nucl Med Commun 15: 533–539, 1994.
Tzen KY, Oster ZH, Wagner HN, et al. Role of iron-binding proteins and enhanced vascular permeability in the accumulation of gallium-67.J Nucl Med 21: 31–35, 1980.
Hosain F, Haddon MJ, Hosain H, et al. Radiopharmaceuticals for diagnosis and treatment of arthritis.Nucl Med Biol 17: 151–155, 1990.
Roizenblatt J, Buchpiguel CA, Menguetti JC, et al. Quantification.of ocular inflammation with technetium-99m glucoheptonate.Eur J Nucl Med 18: 955–958, 1991.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ercan, M.T., Gülaldi, N.C.M., Ünsal, I.S. et al. Evaluation of Tc-99m(V) DMSA for imaging inflammatory lesions: An experimental study. Ann Nucl Med 10, 419–423 (1996). https://doi.org/10.1007/BF03164803
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03164803